Internis Pharmaceuticals develops, manufactures, and supplies prescription vitamin D medicines for the United Kingdom market.
Business Model:
Revenue: $0
Employees: 11-50
Internis Pharma was acquired by
STADA Arzneimittel AG.
The acquisition happend on 2015-06-05.
Details of the transaction were not public
Address:
City: London
State: England
Zip:
Country: United Kingdom
Internis is an exciting and innovative British start-up business. Founded in 2010, it is a pharmaceutical company engaged in the development and commercialisation of highly effective and innovative new medicines aimed at the treatment and prevention of a range of common bone disorders, such as osteoporosis and vitamin D3 deficiency. Internis supplies a prescription only licensed medicine (FultiumD3) to treat patients with a vitamin D deficiency. Vitamin D is offered to at-risk groups on prescription to prevent the health risks associated with a deficiency or insufficiency. It is estimated that up to a quarter of the population in the UK have low levels of vitamin D in their blood – with deficiency linked to conditions including bone deformities and health complications such as depression, joint pain, migraines, fatigue and a weakened immune system.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2013 | Debt Financing | 1 | $3.1M |
Norgine Ventures Norgine Ventures |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|